• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Respiratory

FDA approves Cipla’s generic albuterol inhaler

April 9, 2020 By Sean Whooley

FDA-logo-new

The FDA approved the first generic version of the Proventil HFA (albuterol sulfate) metered-dose inhaler for treating bronchospasm. The FDA indicated the generic inhaler from Cipla for the treatment or prevention of bronchospasm in patients four years of age or older with reversible obstructive airway disease. It also aids in the prevention of exercise-induced bronchospasm […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Respiratory Tagged With: cipla, FDA

OncoSec, Inovio testing COVID-19 vaccines

April 8, 2020 By Sean Whooley

OncoSec Medical (NSDQ:ONCS) and Inovio Pharmaceuticals (NSDQ:INO) announced that they are testing potential COVID-19 vaccines after the latter received investigational new drug clearance from the FDA. Inovio received an IND nod, while OncoSec’s is pending, but both companies are pursuing a first-in-human Phase 1 clinical trial for their vaccines, according to separate news releases. OncoSec is using […]

Filed Under: Business/Financial News, Clinical Trials, Discovery, Featured, Food & Drug Administration (FDA), Immunotherapy, Pharmaceuticals, Preclinical Trials, Regulatory/Compliance, Research & Development, Respiratory Tagged With: coronavirus, COVID-19, Inovio Pharmaceuticals, OncoSec Medical

CF PharmTech raises $90m

January 2, 2020 By Sean Whooley

Pharmaceutical company CF PharmTech, which focuses on respiratory treatments, announced today that it raised $90 million in a Series E financing round. Shuzhou, China–based CF PharmTech said the latest round of funding reflects strong support from China’s investors and will allow the company to bring new products from its pipeline to market. The company produces […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Respiratory Tagged With: CF PharmTech

Propeller Health offers access to CVS, other pharmacies with Propeller app

November 19, 2019 By Sean Whooley

Propeller Health updated logo

Propeller Health announced today that users of its Propeller app are now able to access pharmacy services from CVS, Walmart, Kroger and Rite-Aid directly through that app. The Madison, Wis.–based company launched the app in January 2019, giving Walgreens patients the option to manage their asthma or chronic obstructive pulmonary disease medication regimen within the mobile app. […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Respiratory Tagged With: Propeller Health

Owlstone Medical partners with Thermo Fisher Scientific for breath biopsies

November 14, 2019 By Danielle Kirsh

owlstone-thermofisher

Owlstone Medical last week announced that it has forged a partnership with Thermo Fisher Scientific‘s (NYSE:TMO) to advance non-invasive breath sampling in disease detection. Through the agreement, both companies will integrate the Thermo Scientific Q Exactive GC Hybrid Quadrupole-Orbitrap MassSpectrometer into Owlstone Medical’s Breath Biopsy platform. The collaboration will hopefully qualify the mass analyzer for […]

Filed Under: Business/Financial News, Diagnostics, Respiratory Tagged With: Owlstone Medical, thermofisherscientific

GSK seeks additional asthma indication for Trelegy Ellipta

October 3, 2019 By Sean Whooley

GlaxoSmithKline, Innoviva, Trelegy Ellipta

GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said yesterday that they filed a supplemental New Drug Application with the FDA, seeking an additional indication for GSK’s Trelegy Ellipta inhaler for the treatment of asthma in adults. The once-daily, single-inhaler triple-therapy device received FDA approval for the treatment of chronic obstructive pulmonary disease in September 2017. Trelegy Ellipta has not […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Respiratory Tagged With: GlaxoSmithKline plc, Innoviva

Boehringer Ingelheim touts Spiolto Respimat inhaler data

October 2, 2019 By Sean Whooley

Boehringer Ingelheim

Boehringer Ingelheim said yesterday that results from a study of its Spiolto Respimat inhaler showed benefits including improving symptoms and lung function in treating chronic obstructive pulmonary disease. The Spiolto Respimat is a soft-mist inhaler designed for the treatment of airflow obstruction in patients with COPD. A pooled analysis exploring COPD treatment with the tiotropium-based […]

Filed Under: Clinical Trials, Respiratory Tagged With: Boehringer Ingelheim Pharmaceuticals

Convexity Scientific raises $4m Series B for Flyp nebulizer

September 27, 2019 By Sean Whooley

Flyp

Convexity Scientific said yesterday that it closed a Series B financing round worth nearly $4 million ahead of the launch of its Flyp nebulizer. Fairfield, Conn.-based Convexity’s funding was led by HighCape Capital with participation from Connecticut Innovations, Benslie International and Stonehenge Capital, according to a news release. The company said the funding is earmarked […]

Filed Under: Drug-Device Combinations, Funding Roundup, Respiratory Tagged With: convexityscientific

Pulmatrix doses first patient in Pulmazole trial

September 19, 2019 By Sean Whooley

Pulmatrix

Pulmatrix (NSDQ:PULM) said yesterday that it dosed the first patient in its Phase II trial of Pulmazole for the treatment of allergic bronchopulmonary aspergillosis asthmatics. The 64-patient study is a randomized, double-blinded, placebo-controlled trial to evaluate the safety and efficacy of three dose levels of the anti-fungal drug itraconazole formulation Pulmazole. The multi-center, four-arm trial will […]

Filed Under: Clinical Trials, Featured, Respiratory Tagged With: Pulmatrix Inc.

Senzer Pharmaceuticals wins CE Mark for cannabinoid inhaler

September 18, 2019 By Sean Whooley

Senzer Pharmaceuticals said yesterday that it has received the CE Mark for its cannabinoid inhaler. London-based Senzer said the Class IIa medical device approval, obtained in a joint project with manufacturing partner Europlaz, is the first-ever granted in the cannabinoid space and will allow the company to accelerate its plans to launch in the UK […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance, Respiratory Tagged With: Europlaz, Senzer Pharmaceuticals

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Interim pages omitted …
  • Page 29
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS